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Abstract
Background: Primary immunodeficiencies include a variety of disorders that render patients more susceptible to
infections. If left untreated, these infections may be fatal. Patients with primary antibody deficiencies are therefore
given prophylactic immunoglobulin G replacement therapy. ColdZyme® Mouth Spray is a medical device intended
to reduce the probability of catching a cold and/or can help shorten the duration of a cold, if used at an early
stage of the infection, by forming a thin protective barrier on the pharyngeal mucous membrane. This is the first
report of this kind in the literature.
Case presentation: The parents of a 12-year-old white boy diagnosed as having common variable
immunodeficiency voluntarily started to let their son use ColdZyme® Mouth Spray to reduce common cold
infections if possible. Prior to using ColdZyme® Mouth Spray, he had recurrent microbial infections of his ears,
sinuses, nose, bronchi, and lungs. He also frequently exhibited continuous rhinorrhea, fungal growth in his oral
cavity, and gingivitis with wounds in his gums. As a consequence, his and his family’s health-related quality of life
was severely compromised. He commenced a twice-daily treatment (morning and evening) with ColdZyme®
Mouth Spray; the weekly administration of immunoglobulin G (Hizentra®) for replacement therapy was continued
throughout this period. Data were retrieved by using a daily diary about infections and symptoms. His guardians
had recorded infection symptoms since he was diagnosed as having common variable immunodeficiency 10 years
earlier to follow the effect of the immunoglobulin G treatment. Shortly after commencement of ColdZyme® Mouth
Spray treatment, he experienced a marked improvement in symptoms and health-related quality of life. His
continuous rhinorrhea disappeared, breathing through his nose was easier, oral fungal infection decreased, and
wounds in his gum tissue healed for the first time in several years.
Conclusions: We observed that when ColdZyme® Mouth Spray was used to reduce common cold viral infection in
a patient with common variable immunodeficiency on immunoglobulin G replacement therapy, secondary
microbial and fungal infections in his oral cavity and oropharynx were also reduced. A controlled study is warranted
to confirm the observed results.
Keywords: Subcutaneous immunoglobulin therapy, Common variable immunodeficiency, Respiratory tract
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Background
Primary immunodeficiency diseases (PIDDs) are diseases
in which the immune system has a defect that is not sec-
ondary to infection, drug effects, toxin exposure, or an-
other disease. Patients with common variable
immunodeficiency (CVID) [1] are prone to upper and
lower respiratory tract infections [2]. In infection-prone
children the disease is defined by a serum (S) immuno-
globulin (Ig) G level from 3 g/L to the lowest normal
reference level for the laboratory and a S-IgA level be-
tween 0.07 g/L and the lowest normal reference level for
the laboratory [3].
The Swedish National Board of Health and Welfare
[4] estimated that there are approximately 200 to 300 in-
dividuals with CVID in Sweden; the Swedish Medical
PID Society estimated that there are approximately 450
individuals with CVID in Sweden [4]. Children and
adults with CVID require lifelong replacement treatment
with IgG retrieved from donor blood [5]. In many coun-
tries, the IgG replacement treatment is given to patients,
including children, as subcutaneous IgG (SCIG) infu-
sions [5, 6]. However, in spite of an adequate IgG
replacement therapy, administered as SCIG or intraven-
ously, a subgroup of patients continues to have frequent re-
spiratory tract infections. As an example, a 2011 study
found that patients with PIDD treated with IgG (Hizentra®)
[7] had an average of five infections a year [8]. There re-
mains, therefore, a great need to prevent and/or alleviate
upper respiratory infections in patients with PIDD.
In the upper respiratory tract, mucous membranes
covered with secreted mucous provide an innate barrier
to infection. Reinforcing this barrier may be a favorable
treatment strategy. In this case report, we report the ef-
fect of creating a physical barrier on the pharyngeal mu-
cosal membrane to prevent or reduce infections in the
upper respiratory tract. The barrier was applied by using
a mouth spray to deliver the barrier solution. The barrier
consists of glycerol, buffer salts, and a psychrophilic cod
trypsin, currently marketed as a medical device,
ColdZyme® Mouth Spray (ColdZyme), by Enzymatica
AB, Lund, Sweden. In the device’s formulation, the com-
bination of glycerol and cod trypsin exerts a barrier
function when applied to the pharyngeal mucous mem-
brane [9]. Glycerol, a natural humectant, attracts and re-
tains nearby liquid and virus particles via absorption due
to its high osmotic activity, while trypsin partly degrades
protein structures presented on the viral capsid, and
thereby reduces the interaction potential between viral
capsids and epithelial cells, resulting in a decreased viral
load. The viral load is of importance as there is a dose–
response function between exposed virus dose (viral
load) and probability of getting infected [10]. A double-
blind placebo-controlled study found that ColdZyme re-
duced rhinovirus infection in the pharynx by reducing
the viral load in comparison to a placebo, and the num-
ber of days with common cold symptoms was reduced
from 6.5 to 3 days in comparison to a placebo [9].
Case presentation
A 12-year-old white boy diagnosed as having CVID vol-
untarily started to use ColdZyme 3 years ago in the hope
that it would prevent infection by the common cold
virus. Since the age of 2 he had received weekly SCIG in-
fusions: Hizentra®, 100 to 150 mg/kg weekly. Five
months before the treatment with ColdZyme, analysis
showed his S-IgG level to be 6.70 g/L; 3 months before
the treatment with ColdZyme his S-IgG level was
6.02 g/L. Prior to treatment with ColdZyme he had re-
current microbial infections of his ears, sinuses, nose,
bronchi, and lungs. He frequently exhibited continuous
rhinorrhea, fungal growth in his oral cavity, and gingi-
vitis with wounds in his gums. As a consequence, his
and his family’s health-related quality of life (HRQL) had
been severely compromised and he usually needed to
stay at home from school at least 1 day per week. The
month of November was often a particularly challenging
month for him because recurrent upper respiratory tract
infections often developed into pneumonia. Prophylactic
treatment with amoxicillin for 9 months had little effect
on the recurrent infections.
His parents commenced a twice daily treatment
(morning and evening) of him with ColdZyme. The dose
of the mouth spray was lower than the recommended
dose of six times per day according to the instructions
on the label. Further, the 15 months of preventative use
was outside the intended use range of ColdZyme; that is,
not to be used for more than 30 consecutive days.
Weekly symptoms (malaise, fever, earache, sore throat,
rhinorrhea, gastrointestinal symptoms, dry cough,
mucus cough, cold sores) were recorded using a two-
graded scale (yes/no) in an infection diary. His guardians
had recorded infection symptoms since he was diag-
nosed as having CVID 10 years earlier, to follow the
effect of the IgG treatment. Thus, historical data on self-
reported infection frequency were available. In addition,
a HRQL-related status such as days spent at home from
school was also recorded. His IgG replacement treat-
ment continued on a weekly basis and after 27 weeks of
ColdZyme treatment, measurement of his S-IgG showed
a level of 7.63 g/L.
Figure 1 shows the percentage of various infection
symptoms he experienced per week during a period of
21 months prior to ColdZyme treatment and for the fol-
lowing 15 months when using ColdZyme. As shown,
there was a pronounced reduction in self-reported infec-
tion symptoms during the ColdZyme treatment period;
in particular, the percentage of symptoms of malaise,
rhinorrhea, and cold sores. It was also noted in the
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infection diary that oral fungal infection decreased and
wounds in his gum tissue decreased and healed. No ad-
verse event was reported during the treatment period.
Figure 2 shows the average number of days per week
he was absent from school due to the severity of infec-
tion symptoms for the same periods as in Fig. 1. During
the ColdZyme treatment period, he was on average away
0.3 days/week due to infections, as compared to an aver-
age of 1.4 days/week when not using ColdZyme.
Discussion
This case report emphasizes the possible importance of
the interplay between viral and bacterial species in
infections and by targeting the viral infection it might
also be possible to prevent secondary bacterial
infections.
When a 12-year-old boy diagnosed as having CVID
used ColdZyme, a medical device against the common
cold, to prevent a common cold it was observed that it
also had an impact on several infection symptoms. The
effect was possibly obtained by strengthening his body’s
natural innate barrier in his oral cavity and oropharynx
toward infection. During the treatment period with
ColdZyme he experienced a marked reduction in infec-
tion symptoms and an improved HRQL. His continuous
rhinorrhea almost disappeared, breathing through his
nose was easier, oral fungal infection decreased, and
Fig. 1 Infection symptoms per week. The average percentage of various infection symptoms per week for a 12-year-old boy diagnosed as having
common variable immunodeficiency and treated weekly with subcutaneous immunoglobulin G (100 to 150 mg/kg/week). ColdZyme was used
twice daily during a period of 15 months and the results are compared to historically collected data for a 21-month period prior to the
ColdZyme treatment
Fig. 2 Absence from school. Average days per week spent at home from school for a 12-year-old boy diagnosed as having common variable
immunodeficiency and treated weekly with subcutaneous immunoglobulin G (100 to 150 mg/kg/week). ColdZyme was used twice daily during a
period of 15 months and the results are compared to historically collected data for a 21-month period prior to the ColdZyme treatment
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wounds in his gum tissue healed for the first time in sev-
eral years. Such a quick onset of action and near total
eradication of infection symptoms in our patient by
treatment with ColdZyme was wholly unexpected, par-
ticularly given that the initial treatment period (October
to November) coincided with the time of year during
which he typically experienced the most severe infec-
tions. Understandably, he and his family were elated at
the improvement in their HRQL following more than
10 years of debilitating recurrent infections. His IgG re-
placement therapy continued during the treatment with
ColdZyme. His S-IgG level was found to be higher after
nearly 7 months of treatment with the spray. One ex-
planation of his higher S-IgG level might be that the re-
duction in frequencies of infections led to a decreased
consumption of IgG and, therefore, a higher level of
these antibodies in his blood circulation. It should be
noted that his parents collected the historical data in the
infection dairy before their son used ColdZyme without
knowing that these data would be used to compare ef-
fects observed when using ColdZyme. He continues to
use ColdZyme.
This is a single case study without a placebo control
group and therefore the results are preliminary. Ran-
domized double-blind placebo-controlled studies are
warranted to confirm the observed results. This case re-
port does not support a recommendation for using
ColdZyme for treatment of primary immunodeficiency.
Conclusions
Patients with CVID are prone to upper and lower re-
spiratory tract infections. Respiratory infectious diseases
are mainly caused by viruses or bacteria that often inter-
act with one another. By using ColdZyme® Mouth Spray
to reduce common cold viral infection it seems it is also
possible to influence secondary microbial and fungal in-
fections in the oral cavity and oropharynx.
Perspective of the patient’s mother
The subcutaneous gamma-globulin treatment has been a
great help for my son, but no matter how he was treated
there were still some small symptoms left such as
wounds in his oral mucosa and gums, which made him
eat less and a constant runny nose that was not only an-
noying for him but which drove the whole family crazy.
Three years ago, my son began using ColdZyme on a
daily basis and my intention was to see if this could help his
immune system in fighting infections. This is exactly what
happened and the number of mild infections declined.
What I did not count on was the unexpected positive
add-on effects upon using ColdZyme. His mouth ulcers
drastically decreased which gave me a very different son.
He can now eat the same food as the rest of us almost
every day without having pain and his weight and height
has increased. Shortly after beginning treatment the con-
stant runny nose symptom also disappeared.
Today, my son is a tall lanky teenager with hope in his
eyes and lots of energy. He will probably always need his
gamma-globulin treatment and I can see that ColdZyme
helps him to reach the last, but very important, piece of
well-being.
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